Myovant eyes third NDA for relugolix after endometriosis readout

An NDA submission for an endometriosis therapy could come early next year from Myovant, whose shares gained $2.49 (14%) to $19.90 Tuesday

Read the full 221 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE